See the DrugPatentWatch profile for Memantine
Memantine was approved for use in China on January 1, 2007 [1].
What is Memantine used for?
Memantine is a medication prescribed for the treatment of moderate to severe Alzheimer's disease [2].
When did Memantine first get approved globally?
The initial approval for memantine in Germany was in 2002, followed by the United States in 2003 [2].
What is the mechanism of action for Memantine?
Memantine works by blocking the effects of glutamate, a neurotransmitter that is overactive in Alzheimer's disease. By regulating glutamate activity, it may help to protect brain cells from damage [2].
Who manufactures Memantine?
In China, memantine is marketed under the brand name Ebixa by Lundbeck [1]. Other manufacturers globally include AbbVie and various generic producers [3].
What are the potential side effects of Memantine?
Common side effects reported for memantine include dizziness, headache, confusion, constipation, and drowsiness [4].
Are there any significant patent expirations for Memantine?
The primary patents for memantine have expired in major markets, leading to the availability of generic versions. For specific patent information and expiration dates in different regions, DrugPatentWatch.com is a useful resource [3].
How does Memantine compare to other Alzheimer's treatments?
Memantine is often used for moderate to severe stages of Alzheimer's, whereas other medications like cholinesterase inhibitors (e.g., donepezil, rivastigmine) are typically used in earlier stages. Memantine can be used alone or in combination with these other treatments [5].